Strategic Relationship with Cato Research and Cato BioVentures

Echo has a strategic development relationship with Cato Research, a leading contract research and development organization (CRO) with over 300 employees worldwide. Cato Research is the core portfolio company of Cato BioVentures, a life science venture capital firm and currently Echo's largest institutional shareholder. Due to its strategic affiliation with Cato BioVentures and its extensive expertise working with medical devices Echo's AzoneTS reformulation platform, Echo has unique strategic access to a wide range of CRO services from Cato Research to support several of its product development and regulatory programs on a discounted and/or deferred payment basis.  Accordingly, Echo expects its Symphony tCGM System and AzoneTS product development activities to remain financially disciplined and heavily based on flexible, real-time strategic outsourcing to Cato Research and other vendors and contract service providers in the pharmaceutical industry to avoid the significant fixed-cost financial and management burden typically associated with building and maintaining a large, fully integrated product development infrastructure. Additionally, Echo's strategic access to Cato Research's pharmaceutical industry client base provides Echo with unique access to a network of prospective pharamceutical partners with interest in development and commercialization of specialty pharmaceuticals and diabetes management products.

Edit Page Add Page